scholarly journals Characteristics of patients who were able to switch from benzodiazepine hypnotics to lemborexant

2021 ◽  
Vol 9 ◽  
pp. 205031212110379
Author(s):  
Hidenobu Suzuki ◽  
Hiroyuki Hibino
Keyword(s):  
Maintenance Therapy ◽  
Outcome Assessment ◽  
Athens Insomnia Scale ◽  
Efficacy Outcome ◽  
Scale Total Score ◽  
Insomnia Treatment ◽  
The Mean ◽  
Term Maintenance ◽  
Improvement Score

Objectives: There is little evidence of insomnia treatment, especially exit strategies for hypnotics. We examined on the characteristics of patients who were able to switch from benzodiazepine hypnotics to lemborexant. Methods: Insomnia was assessed using the Athens Insomnia Scale. Efficacy outcome assessment was the Clinical Global Impressions-Improvement scale. Results: Eighty patients switched from benzodiazepine hypnotic monotherapy to lemborexant and 57 patients who continued the use of benzodiazepine hypnotics. The switched group had a significantly lower benzodiazepine hypnotic diazepam equivalent and a significantly shorter dosing period than the continued group ( p < 0.001 for all). The mean Athens Insomnia Scale total score of the switched group was a significant improved (5.8 ± 3.3 to 4.0 ± 3.3; p < 0.05). The mean Clinical Global Impressions-Improvement score of the switched group was 3.3 ± 0.7. Conclusion: Our findings suggest that when administering benzodiazepine hypnotics, shortening the administration period, as much as possible, allows a smooth switch to safe long-term maintenance therapy using lemborexant, without exacerbating insomnia.

Efficacious long-term maintenance therapy with pantoprazole (PAN) in patients with Zollinger-Ellison syndrome

2001 ◽  
Vol 120 (5) ◽  
pp. A613-A613
Author(s):  
P BORNMAN ◽  
K RADEBOLD ◽  
H DEBAERE ◽  
L VENTER ◽  
H HEINZE ◽  
...  
Keyword(s):  
Maintenance Therapy ◽  
Zollinger Ellison Syndrome ◽  
Term Maintenance

scholarly journals Substantiation of Using Pimecrolimus 1% Cream in Proactive Therapy of Children with Atopic Dermatitis

2021 ◽  
Vol 20 (5) ◽  
pp. 376-382
Author(s):  
Nikolay N. Murashkin ◽  
Roman A. Ivanov ◽  
Eduard T. Ambarchian ◽  
Roman V. Epishev ◽  
Alexander I. Materikin ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Maintenance Therapy ◽  
Skin Disease ◽  
Pediatric Population ◽  
Efficacy And Safety ◽  
Inflammatory Skin Disease ◽  
High Prevalence ◽  
Proactive Therapy ◽  
Term Maintenance

Atopic dermatitis (AtD) is multifactorial inflammatory skin disease with high prevalence in pediatric population. It is crucial to implement long-term maintenance therapy to prevent AtD exacerbations according to current clinical guidelines and expert reports. The article summarizes the results of the major studies on using pimecrolimus 1% cream. Its efficacy and safety in long-term proactive therapy of children with AtD are presented.

scholarly journals The effect of lemborexant for insomnia disorder

2021 ◽  
Vol 9 ◽  
pp. 205031212110390
Author(s):  
Hidenobu Suzuki ◽  
Hiroyuki Hibino
Keyword(s):  
Clinical Practice ◽  
Average Dose ◽  
Relaxant Effect ◽  
Athens Insomnia Scale ◽  
Subjective Evaluations ◽  
Duration Of Illness ◽  
Insomnia Disorder ◽  
Efficacy Outcome ◽  
The Mean ◽  
Objective Indicators

Background: Lemborexant has a low dependence potential, less muscle relaxant effect, and less effect on cognitive function. However, there have been no naturalistic reports in Japan clarifying the effect of lemborexant on insomnia disorder. We retrospectively examined the effectiveness of treatment with lemborexant. Methods: Insomnia was assessed using the Athens Insomnia Scale (AIS). Efficacy outcome assessment was the Clinical Global Impressions–Improvement scale (CGI-I). Results: We analyzed 150 patients (male/female = 57/93) in total. The mean subject age and mean duration of illness were 47.8 ± 19.9 years and 4.2 ± 7.2 years, respectively. The average dose of lemborexant was 5.9 ± 2.0 mg. The mean AIS total score was a significant improved (6.6 ± 3.7–3.9 ± 3.3) ( p < 0.01). The mean CGI-I score was 3.2 ± 0.8. The 24-week continuation rates for lemborexant were 86.7%. Conclusion: Similar to the results obtained in previous studies, the CGI-I score, which is one of the objective indicators evaluated by the therapist, and the AIS, which is one of the subjective evaluations of patients, improved as well. The results of this study suggest that lemborexant may be safe and effective in patients with insomnia in real-world clinical practice.

Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine

2008 ◽  
Vol 54 (5) ◽  
pp. 955-963 ◽  
Author(s):  
David A. Peura ◽  
James W. Freston ◽  
Marian M. Haber ◽  
Thomas O. Kovacs ◽  
Barbara Hunt ◽  
...  
Keyword(s):  
Maintenance Therapy ◽  
Erosive Esophagitis ◽  
Double Blind ◽  
Blind Comparison ◽  
Term Maintenance

A Practical Approach to the Use of Acitretin for the Treatment of Psoriasis

2010 ◽  
Vol 16a (2) ◽  
pp. 62-68
Author(s):  
Tina Bhutani ◽  
Kristine Busse
Keyword(s):  
Side Effects ◽  
Adverse Events ◽  
Maintenance Therapy ◽  
Plaque Psoriasis ◽  
Practical Approach ◽  
Serious Adverse Events ◽  
Oral Retinoid ◽  
Systemic Agents ◽  
Term Maintenance

This clinical review outlines a practical approach to the use of acitretin in the treatment of psoriasis. Acitretin is approved by the Food and Drug Administration for the treatment of adult patients with chronic moderate to severe plaque psoriasis. It is an oral retinoid and is the only systemic agent that is not clinically immunosuppressive; it works primarily by enhancing differentiation and maturation of cells. Side effects associated with this medication are usually mild and manageable; serious adverse events are rare. Therefore, it can be used for long-term maintenance therapy or in combination with other topical or systemic agents and phototherapy.

Sign in / Sign up

Export Citation Format

Share Document